Table 1 Pushing availability: Adoptive cell transfer therapies for cancer are available only at a few medical centres right now, but several companies are working to change that.

From: Adoptive cell therapy: Honing that killer instinct

Company

Therapy Type

Partnerships and trials

Adaptimmune

T-cell receptor (TCR)

Sponsoring nine pilot and phase I trials at several medical centres in the United States

Novartis

Chimaeric antigen receptor (CAR)

Licensing agreement with University of Pennsylvania to develop therapies. Establishing a global clinical trial program for CTL019, and expects to expand trials in the US next year.

Lion Biotechnologies

Tumour-infiltrating lymphocyte (TIL)

Licensing agreement with NCI to develop TIL for treating Stage IV metastatic melanoma

Kite Pharma

TCR, CAR

Agreement with the US National Cancer Institute to develop and commercialize products

Back to article page